Table 1 Baseline characteristics of the study population.
Characteristics | Overall n = 87,980 | AMI n = 38,246 | Angina n = 49,734 |
|---|---|---|---|
Age, years | 65 (56–74) | 63 (54–74) | 66 (57–74) |
Male | 62,776 (71.4) | 29,172 (76.3) | 33,604 (67.6) |
Comorbid conditions | |||
Diabetes | 29,814 (33.9) | 10,416 (27.2) | 19,398 (39.0) |
Hyperlipidemia | 37,108 (42.2) | 11,365 (29.7) | 25,743 (51.8) |
Hypertension | 51,986 (59.1) | 18,428 (48.2) | 33,558 (67.5) |
History of heart failure | 5,538 (6.3) | 1,297 (3.4) | 4,241 (8.5) |
Cardiac arrhythmia | 5,768 (6.6) | 1,254 (3.3) | 4,514 (9.1) |
Valvular heart disease | 284 (0.3) | 60 (0.2) | 224 (0.5) |
Peripheral vascular disorder | 9,926 (11.3) | 3,318 (8.7) | 6,608 (13.3) |
Cerebrovascular disease | 10,605 (12.1) | 3,153 (8.2) | 7,452 (15.0) |
Chronic pulmonary disease | 11,838 (13.5) | 4,186 (10.9) | 7,652 (15.4) |
Moderate-to-severe liver disease | 34 (0.04) | 13 (0.03) | 21 (0.04) |
Renal disease | 4,089 (4.6) | 1,163 (3.0) | 2,926 (5.9) |
Malignancy | 1,749 (2.0) | 642 (1.7) | 1,107 (2.2) |
Rheumatic disease | 143 (0.2) | 49 (0.1) | 94 (0.2) |
Charlson comorbidity index | 1 (0–2) | 1 (0–2) | 1 (0–2) |
Type of treatment for PCI | |||
Drug-eluting stent | 82,310 (93.6) | 36,011 (94.2) | 46,299 (93.1) |
Bioresorbable vascular scaffold | 568 (0.6) | 250 (0.7) | 318 (0.6) |
Bare-metal stent | 599 (0.7) | 276 (0.7) | 323 (0.6) |
Plain balloon angioplasty | 4,503 (5.1) | 1,709 (4.5) | 2,794 (5.6) |
Number of stents per person | 1 (1–2) | 1 (1–2) | 1 (1–2) |
Medication at discharge | |||
Aspirin | 82,567 (93.8) | 36,067 (94.3) | 46,500 (93.5) |
P2Y12 receptor antagonists | 87,194 (99.1) | 37,107 (99.6) | 49,087 (98.7) |
Statins | 80,669 (91.7) | 36,324 (95.0) | 44,345 (89.2) |
ACEI or ARBs | 56,389 (64.1) | 27,264 (71.3) | 29,125 (58.6) |
